Drugs / V505
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00520598 | Oct 2007 → May 2011 | anogenital human papillomavirus infection, cervical cancer, vaginal cancer, vulva cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00520598 ↗ |
| Modality | Vaccine | “V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine)” NCT00520598 ↗ |